HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem responds to CARU

This article was originally published in The Rose Sheet

Executive Summary

Chattem agrees to pull TV spot for pHisoderm Clear Confidence Clear Swabfrom children's programming in response to ad review by the Children's Advertising Review Unit, the Council of Better Business Bureaus division says. Chattem did not intend for commercial to air during TV shows directed to young children, and will try to ensure future commercials of this nature do not run during children's programs, CARU states. In a recent inquiry, CARU pointed out its guidelines recommend against advertising medication to children (1"The Rose Sheet" May 19, 2003, p. 5)...

You may also be interested in...



J&J’s Neutrogena, Chattem’s Phisoderm Ads Reviewed By CBBB

Johnson & Johnson agreed to permanently discontinue a TV ad for Neutrogena Deep Clean Gentle Scrub comparing the product's exfoliating properties to competitor formulas following a review by the National Advertising Division of the Council of Better Business Bureaus, according to NAD

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy

The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel